Arthritis FAQ — Common Questions About Joint Pain and Inflammation Treatment

Arthritis means "joint inflammation" and describes over 100 different conditions affecting joints and surrounding tissues. Affects approximately 350 million people worldwide.

Main types:

• Osteoarthritis (OA) - most common; wear-and-tear cartilage breakdown
• Rheumatoid arthritis (RA) - autoimmune disease attacking joints symmetrically
• Gout - crystal-induced arthritis from high uric acid
• Psoriatic arthritis - associated with psoriasis
• Ankylosing spondylitis - spine and sacroiliac joint inflammation
• Juvenile arthritis - in children under 16
• Lupus arthritis - part of systemic lupus
• Infectious arthritis - bacterial or viral infection

Each type has different causes, treatments, and prognoses. Diagnosis by rheumatologist essential for proper treatment. Modern medications like Arcoxia, Arava, Olumiant, and Zyloprim transformed arthritis care.

Causes vary by arthritis type:

Osteoarthritis causes:

• Age - cartilage wears down over time
• Joint injuries - previous trauma
• Obesity - extra stress on joints
• Genetics - family history
• Repetitive stress - occupation, sports
• Bone deformities

Rheumatoid arthritis causes:

• Autoimmune reaction - immune system attacks joints
• Genetic predisposition
• Environmental triggers (smoking major factor)
• Hormonal factors (women 3x more affected)
• Possibly infections as triggers

Gout causes:

• High uric acid levels in blood
• Genetics - major factor
• Diet - red meat, seafood, alcohol
• Obesity
• Kidney disease
• Certain medications (diuretics)

Understanding cause guides treatment. Autoimmune arthritis needs DMARDs like Arava or Lefuheal, gout needs urate-lowering therapy like Zyloprim.

RXshop offers 5 arthritis medications across major classes:

NSAIDs (COX-2 inhibitor):

• Arcoxia (Etoricoxib 60mg) - selective COX-2 inhibitor

DMARDs (Disease-Modifying Anti-Rheumatic Drugs):

• Arava (Leflunomide 10mg)
• Lefuheal (Leflunomide 10mg) - alternative brand

JAK inhibitors (targeted synthetic DMARD):

• Olumiant (Baricitinib 4mg)

Urate-lowering therapy (gout):

• Zyloprim (Allopurinol 300mg)

Related pain relief may include NSAIDs from the anti-inflammatories category. Selection depends on arthritis type, severity, comorbidities, and treatment response.

Joint symptoms common to most arthritis:

• Pain - most common; varies by activity
• Stiffness - morning or after inactivity
• Swelling - warmth, redness in inflammatory types
• Reduced range of motion
• Grinding sensations (crepitus in OA)
• Weakness around joint
• Joint deformity in advanced disease

Type-specific patterns:

• Osteoarthritis: asymmetric, pain with activity, stiffness less than 30 minutes
• Rheumatoid arthritis: symmetric small joints, morning stiffness over 1 hour, fatigue
• Gout: sudden severe pain, often big toe, red hot swollen joint
• Ankylosing spondylitis: lower back pain, improves with exercise

Systemic symptoms (autoimmune types):

• Fatigue
• Low-grade fever
• Weight loss
• Skin rashes (psoriatic, lupus)
• Eye inflammation
• Muscle aches

Symptom duration matters: transient joint pain is often not arthritis. Persistent symptoms lasting weeks warrant medical evaluation.

Arcoxia (Etoricoxib 60mg) is a selective COX-2 inhibitor providing anti-inflammatory and analgesic effects with better GI tolerability than traditional NSAIDs.

How it works:

Common uses:

• Osteoarthritis pain and inflammation
• Rheumatoid arthritis symptom control
• Ankylosing spondylitis
• Acute gouty arthritis
• Acute musculoskeletal pain
• Post-surgical pain

Advantages: once-daily dosing, effective anti-inflammatory action, lower GI ulcer risk than ibuprofen/naproxen.

Important warnings:

• Cardiovascular risk - CONTRAINDICATED in established heart disease
• Blood pressure elevation
• Kidney effects
• Not for stroke/MI risk patients
• Regular blood pressure monitoring needed

Arava (Leflunomide 10mg) and Lefuheal (Leflunomide 10mg) are conventional synthetic DMARDs (Disease-Modifying Anti-Rheumatic Drugs) that not only relieve symptoms but slow disease progression.

How leflunomide works:

Uses:

• Rheumatoid arthritis (primary)
• Psoriatic arthritis
• Sometimes off-label autoimmune conditions
• Alone or with other DMARDs (methotrexate)
• Alternative when methotrexate not tolerated

Critical warnings:

• Hepatotoxicity - regular liver monitoring
• Bone marrow suppression
• Serious infections - suppressed immunity
• TERATOGENIC - contraception essential for BOTH partners
• Very long half-life (weeks) - washout procedure if pregnancy planned
• TB screening before starting

Olumiant (Baricitinib 4mg) is a JAK (Janus kinase) inhibitor - modern targeted synthetic DMARD offering oral alternative to injectable biologics.

How JAK inhibitors work:

Uses:

• Moderate to severe rheumatoid arthritis - when conventional DMARDs fail
• Alopecia areata
• Severe atopic dermatitis
• COVID-19 (hospitalized patients on oxygen)

Advantages over injectable biologics:

• Oral administration
• No antibody development
• Faster onset
• More convenient dosing

Zyloprim (Allopurinol 300mg) is the most commonly prescribed urate-lowering medication for chronic gout prevention.

How allopurinol works:

Uses:

• Chronic gout (primary indication)
• Tophaceous gout (visible urate deposits)
• Uric acid kidney stones
• Tumor lysis syndrome prevention
• Certain rare metabolic conditions

Critical usage rules:

• Do NOT start during acute attack - can worsen it
• Start low, go slow - reduces flare risk
• Use colchicine/NSAID coverage for first 3-6 months
• Target uric acid under 6 mg/dL
• Lifelong treatment for chronic gout
• Do NOT stop after uric acid normalizes
• Missing doses can trigger attacks

HLA-B*5801 screening recommended in Asian populations - severe skin reaction risk. Report any rash immediately.

Acute gout attacks require different treatment than long-term prevention. Start treatment as early as possible - within hours of attack onset for best results.

First-line acute treatments:

• NSAIDs - like Arcoxia (Etoricoxib) - if no contraindications
• Colchicine - especially early in attack
• Corticosteroids - oral prednisone or intra-articular injection

Important during acute attack:

• Rest affected joint
• Ice application (short periods)
• Elevate joint
• Adequate hydration
• Avoid alcohol and purine-rich foods

Key rules:

• Continue urate-lowering therapy if already on it - do NOT stop Zyloprim during attack
• Do NOT start allopurinol during acute attack - can worsen it
• Start urate-lowering AFTER acute attack resolves
• Attacks typically resolve in 7-10 days with treatment

Untreated attacks may last weeks. Recurrent attacks require prevention with urate-lowering therapy.

Arthritis diagnosis requires comprehensive evaluation including history, physical examination, laboratory tests, and imaging.

Clinical assessment:

• Detailed medical and family history
• Pattern of joint involvement (which joints, symmetric?)
• Symptom duration and progression
• Morning stiffness duration
• Extra-articular symptoms
• Physical examination of joints

Laboratory tests:

• Complete blood count (CBC) - anemia, elevated white cells
• ESR and CRP - inflammation markers
• Rheumatoid factor (RF) - for RA
• Anti-CCP antibodies - more specific for RA
• ANA - autoimmune diseases
• Uric acid - gout
• Joint fluid analysis - definitive for gout, infection
• HLA-B27 - ankylosing spondylitis

Imaging:

• X-rays - joint damage, bone spurs, erosions
• MRI - early inflammation, soft tissue
• Ultrasound - synovial inflammation
• CT scan - complex joint anatomy

Diagnosis by rheumatologist ensures accurate identification of arthritis type and appropriate treatment planning.

Most arthritis types cannot be cured but can be effectively managed with proper treatment.

Non-curable but manageable:

• Osteoarthritis - progressive but treatable; joint replacement effective for severe cases
• Rheumatoid arthritis - remission possible with early aggressive treatment
• Ankylosing spondylitis - controllable with treatment
• Psoriatic arthritis - controllable

Modern treatment achievements:

• Clinical remission possible for many RA patients with DMARDs like Arava and JAK inhibitors like Olumiant
• Slowed disease progression
• Prevention of joint damage
• Restored quality of life
• Prevention of disability

Curable arthritis conditions:

• Infectious arthritis - antibiotics can cure bacterial infections
• Some reactive arthritis - can resolve completely

For gout: disease itself is controlled with Zyloprim, though not cured. Attacks preventable with proper treatment.

Early aggressive treatment for autoimmune arthritis prevents joint damage and disability - the difference between mild and severe long-term outcomes.

While most arthritis cannot be entirely prevented, risk reduction and early intervention improve outcomes.

Osteoarthritis prevention:

• Maintain healthy weight - reduces knee/hip OA risk
• Regular exercise - keeps joints and muscles strong
• Avoid joint injuries - proper form in sports
• Balanced diet - anti-inflammatory foods
• Adequate calcium and vitamin D
• Avoid repetitive stress
• Address joint injuries promptly

Rheumatoid arthritis prevention:

• Do not smoke - smoking major risk factor
• Maintain oral health - gum disease linked to RA
• Address periodontal disease
• Family history awareness - early evaluation of symptoms

Gout prevention:

• Limit purine-rich foods - red meat, seafood, organ meats
• Limit alcohol - especially beer
• Avoid high-fructose corn syrup
• Stay well-hydrated
• Maintain healthy weight
• Dairy consumption may help
• Vitamin C - modest reduction

General measures: stay active, maintain healthy weight, avoid smoking, eat anti-inflammatory diet, manage stress, get adequate sleep.

Lifestyle modifications are essential for arthritis management alongside medications.

Exercise:

• Low-impact aerobic exercise - swimming, cycling, walking
• Strength training - supports joints
• Range of motion exercises - maintains flexibility
• Tai chi and yoga - improve balance and flexibility
• Aim for 30 minutes most days

Weight management:

• Even 5-10 pounds loss significantly reduces knee OA symptoms
• Reduces stress on weight-bearing joints
• Improves treatment response

Anti-inflammatory diet:

• Mediterranean diet (fruits, vegetables, olive oil, fish)
• Omega-3 fatty acids (fish, flaxseed)
• Colorful fruits and vegetables
• Whole grains
• Limit red meat, processed foods, sugar

For gout specifically:

• Limit red meat, organ meats, seafood
• Avoid high-fructose corn syrup
• Limit alcohol (especially beer)
• Adequate hydration
• Cherries may help

Other important measures:

• Adequate sleep (7-9 hours)
• Stress management
• Quit smoking (major factor for RA)
• Hot/cold therapy
• Physical therapy
• Assistive devices when needed

CONTRAINDICATED in pregnancy:

• Leflunomide (Arava, Lefuheal) - severe teratogenic effects; contraception essential for BOTH partners; washout procedure required if pregnancy planned
• Methotrexate - teratogenic
• NSAIDs including Arcoxia - avoid especially in third trimester
• JAK inhibitors including Olumiant - limited pregnancy data

Generally safer options:

• Hydroxychloroquine - safe throughout pregnancy
• Sulfasalazine - with folic acid supplementation
• Certain biologics - after risk-benefit discussion
• Corticosteroids - low doses
• Paracetamol/acetaminophen - for pain

Important considerations:

• RA often improves during pregnancy
• Postpartum flares common
• Pre-pregnancy planning essential
• Individual risk-benefit assessment
• Untreated arthritis also carries risks

For gout: Zyloprim use during pregnancy limited to serious situations. Always discuss with rheumatologist and obstetrician.

Juvenile arthritis affects approximately 300,000 US children. Pediatric rheumatology care essential for proper treatment.

Treatment considerations:

• Weight-based dosing
• Pediatric-approved formulations
• Growth and development monitoring
• Longer treatment duration considerations
• Vaccination scheduling important

Commonly used in children:

• NSAIDs - short-term pain relief
• Methotrexate - most common pediatric DMARD
• Sulfasalazine - alternative DMARD
• Certain biologics - approved for juvenile arthritis
• Corticosteroids - for flares

Medications with pediatric limitations:

• Leflunomide (Arava) - limited pediatric data
• JAK inhibitors like Olumiant - approved for some pediatric conditions
• COX-2 inhibitors - limited pediatric approval
• Zyloprim - rarely needed in children (gout uncommon)

Comprehensive care includes:

• Physical and occupational therapy
• School accommodations
• Psychological support
• Age-appropriate exercise
• Nutrition support
• Vision screening (for uveitis)

Early aggressive treatment prevents long-term disability. Consult pediatric rheumatologist for proper management.

Side effects vary by medication class:

NSAIDs (Arcoxia):

• Stomach upset, ulcers, bleeding
• Cardiovascular risks (heart attack, stroke)
• Blood pressure elevation
• Kidney effects
• Fluid retention
• Allergic reactions

DMARDs (Arava, Lefuheal):

• Diarrhea (very common with leflunomide)
• Liver toxicity
• Bone marrow suppression
• Serious infections
• Hair thinning
• Rash
• Hypertension
• Peripheral neuropathy

JAK inhibitors (Olumiant):

• Serious infections (TB reactivation)
• Malignancies
• Cardiovascular events
• Blood clots (DVT, PE)
• Herpes zoster reactivation
• Elevated cholesterol
• Liver enzyme abnormalities

Allopurinol (Zyloprim):

• Skin rash
• Stevens-Johnson syndrome (rare but serious)
• Liver enzyme elevation
• Initial gout flares (paradoxical)
• GI upset

Report immediately: rash, difficulty breathing, severe abdominal pain, yellowing of skin, signs of infection, unusual bleeding.

Arthritis medications have important interactions requiring careful medication management.

NSAIDs (Arcoxia) interactions:

• Warfarin - increased bleeding risk
• ACE inhibitors, ARBs, diuretics - reduced blood pressure control
• Lithium - increased levels
• Methotrexate - increased toxicity
• Aspirin - increased GI bleeding
• Other NSAIDs - never combine

Leflunomide interactions:

• Warfarin - variable effects on INR
• Rifampin - increased leflunomide levels
• Live vaccines - AVOID
• Other hepatotoxic drugs - increased liver toxicity
• Cholestyramine - used for washout

Olumiant interactions:

• Strong immunosuppressants - AVOID combining
• Other DMARDs - use cautiously
• Live vaccines - CONTRAINDICATED
• Probenecid - increased baricitinib levels

Allopurinol interactions:

• Azathioprine and 6-MP - CRITICAL interaction, life-threatening toxicity
• Warfarin - increased anticoagulation
• ACE inhibitors - increased hypersensitivity risk
• Thiazide diuretics - increased hypersensitivity

Always inform all providers about ALL medications, supplements, and OTC drugs. Pharmacist review essential.

Duration depends on arthritis type and medication:

Osteoarthritis medications:

• NSAIDs typically as-needed for pain
• Long-term use requires monitoring
• Chronic OA often requires ongoing pain management
• Consider topical NSAIDs for long-term use

Rheumatoid arthritis treatment:

• DMARDs like Arava typically LONG-TERM
• Continued in remission to prevent flares
• Reducing but not stopping when stable
• Never stop suddenly - can trigger severe flares
• Discontinuation only under specialist supervision

Gout prevention with allopurinol:

• Lifelong treatment typically
• Do not stop after uric acid normalizes
• Stopping triggers attacks
• Continue during acute attacks

JAK inhibitors like Olumiant:

• Continued as long as effective
• Regular reassessment needed
• Consider dose reduction in stable patients
• Monitor for cumulative risks

Key principle: chronic arthritis usually requires chronic treatment. Stopping medications when feeling well often leads to disease flares. Discuss any changes with rheumatologist.

DMARDs (Disease-Modifying Anti-Rheumatic Drugs) and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) have fundamentally different roles in arthritis treatment.

NSAIDs (Arcoxia):

• Provide symptom relief - pain and inflammation
• Fast onset (hours)
• Do NOT slow disease progression
• Do NOT prevent joint damage in autoimmune arthritis
• Used as-needed or short courses
• Cardiovascular and GI risks with long-term use

DMARDs (Arava, Lefuheal):

• Modify disease course - slow or stop progression
• Prevent joint damage in autoimmune arthritis
• Slower onset (weeks to months)
• Continuous treatment required
• Require blood monitoring
• Suppress immune system

Categories of DMARDs:

• Conventional synthetic (csDMARDs) - methotrexate, leflunomide, sulfasalazine
• Biologic (bDMARDs) - TNF inhibitors, other biologics
• Targeted synthetic (tsDMARDs) - JAK inhibitors like Olumiant

Treatment strategy: NSAIDs for symptom control WHILE DMARDs work; DMARDs prevent long-term damage. Both often used together in autoimmune arthritis.

Non-medication treatments are essential alongside arthritis medications for optimal outcomes.

Physical therapy:

• Improves joint function and range of motion
• Strengthens supporting muscles
• Reduces pain
• Provides customized exercise programs
• Teaches joint protection strategies

Occupational therapy:

• Adapts daily activities
• Assistive devices (jar openers, reachers)
• Home modifications
• Work accommodations
• Splints and braces

Exercise programs:

• Low-impact: swimming, cycling, walking
• Water aerobics - excellent for arthritis
• Tai chi and yoga - flexibility and balance
• Strength training - protects joints
• Regular exercise reduces pain and stiffness

Weight management:

• Critical for OA of weight-bearing joints
• Even small losses provide big benefits
• Reduces disease burden

Complementary approaches:

• Heat and cold therapy
• Massage therapy
• Acupuncture (some evidence for OA)
• Meditation and mindfulness

Surgical options:

• Joint replacement (knee, hip)
• Joint fusion
• Synovectomy
• Tendon repair

Assistive devices: canes, walkers, braces, orthotics improve function and reduce pain. Combined with medications provides optimal outcomes.

Starting arthritis medications requires careful preparation and monitoring.

Before starting:

• TB screening - required for biologics and JAK inhibitors like Olumiant
• Hepatitis B/C screening
• Baseline blood work - CBC, liver enzymes, kidney function
• Vaccination updates - especially before immunosuppressive medications
• Live vaccines - complete BEFORE starting DMARDs
• Pregnancy planning discussions
• HLA testing - for allopurinol in high-risk populations

During treatment monitoring:

• Regular blood tests - varies by medication
• Liver function (leflunomide, allopurinol, others)
• Blood counts (DMARDs)
• Kidney function
• Lipid panels (JAK inhibitors)
• Blood pressure (NSAIDs)

Warning signs to report:

• Rash - especially serious with Zyloprim
• Signs of infection
• Yellowing of skin or eyes
• Unusual bleeding or bruising
• Severe fatigue
• New neurological symptoms
• Pregnancy or planning pregnancy

Follow-up appointments essential - typically every 3-6 months during stable treatment, more often when starting or changing medications.

See doctor promptly for:

• Persistent joint pain lasting more than 2 weeks
• Morning stiffness lasting over 30 minutes
• Joint swelling, redness, warmth
• Symmetric joint involvement
• Difficulty performing daily activities
• Unexplained weight loss with joint pain
• Fatigue with joint pain
• Family history of autoimmune disease
• First-ever gout attack
• Frequent gout attacks
• Any joint deformity developing
• Skin changes with joint pain

Regular follow-up needed for:

• All chronic arthritis conditions
• Medication monitoring
• Disease activity assessment
• Response to treatment
• Side effect surveillance
• Vaccination updates

Rheumatologist referral for autoimmune arthritis, complex cases, treatment failures, and consideration of biologics or JAK inhibitors. Early aggressive treatment prevents disability - do not delay evaluation.